Publications by authors named "Exeli A"
Article Synopsis
- A case study highlights the use of a large myomatous uterus as a natural spacer during radiation therapy for a female patient with locally advanced anal carcinoma, helping to protect the bowel from excess radiation exposure.
- The patient initially presented with anal pain, and subsequent examinations confirmed a diagnosis of squamous cell carcinoma, with imaging revealing a large uterus containing multiple leiomyomas.
- The presence of these leiomyomas minimized the radiation dose to the small intestine, leading to virtually no acute gastrointestinal toxicity during the patient's chemoradiation treatment.
Background: We retrospectively investigate feasibility and safety of whole brain radiotherapy (WBRT) including a simultaneous-integrated boost technique (WBRT-SIB) in a cohort of patients with a very poor prognosis suffering from multiple and/or large brain metastases, unfavorable primary histology, poor performance status and/or symptomatic BMs.
Materials And Methods: Thirty-five patients with high brain tumor burden, extracranial metastases and low life-expectancy were treated with WBRT-SIB mostly with 35-42 Gy/14 fractions. All metastases were boosted in patients with up to 12 BMs.
Background: To date, patients with glioblastoma still have a bad median overall survival rate despite radiation dose-escalation and combined modality treatment. Neurocognitive decline is a crucial adverse event which may be linked to high doses to the cortex. In a planning study, we investigated the impact of dose constraints to the cerebral cortex and its relation to the organs at risk for glioblastoma patients.
View Article and Find Full Text PDFBackground: To report acute and late toxicity with long-term follow-up, and to describe our experiences with pulmonary dose constraints.
Methods: Between 2002 and 2009, 150 patients with 155 histologically/cytologically proven non-small cell lung cancer (NSCLC; tumor stages II, IIIA, IIIB in 6, 55 and 39%, respectively) received the following median doses: primary tumors 79.2 Gy (range 72.
Background: One of the primary dose-limiting toxicities during thoracic irradiation is acute esophagitis (AE). The aim of this study is to investigate dosimetric and clinical predictors for AE grade ≥ 2 in patients treated with accelerated radiotherapy for locally advanced non-small cell lung cancer (NSCLC).
Patients And Methods: 66 NSCLC patients were included in the present analysis: 4 stage II, 44 stage IIIA and 18 stage IIIB.